Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-001705
Abstract: Aim Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR… read more here.
Keywords: metastatic colorectal; cetuximab; colorectal cancer; selection patients ... See more keywords